American Heart Journal
Volume 146, Issue 1 , Pages 9-18 , July 2003

Vasopressin: a new target for the treatment of heart failure

  • Craig R Lee, PharmD

      Affiliations

    • School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Michael L Watkins, PharmD

      Affiliations

    • GlaxoSmithKline, Research Triangle Park, NC, USA
    • ,
  • J.Herbert Patterson, PharmD

      Affiliations

    • School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • Departments of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Wendy Gattis, PharmD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Christopher M O’Connor, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University Medical School, Chicago, Ill, USA
    • ,
  • Kirkwood F Adams Jr, MD

      Affiliations

    • Departments of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • Corresponding Author InformationReprint requests: Kirkwood F. Adams, Jr, MD, Division of Cardiology, University of North Carolina at Chapel Hill, CB# 7075, 342 Burnett-Womack Building, Chapel Hill, NC 27599-7075, USA

Received 4 June 2002 ,Accepted 8 August 2002.

References 

  1. Schrier RW, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
  2. Heart Failure Society of America . HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. J Card Fail. 1999;5:357–382
  3. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol. 1983;244:E72–82
  4. Thibonnier M, Auzan C, Madhun Z, et al.  Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994;269:3304–3310
  5. Nielsen S, Kwon TH, Christensen BM, et al.  Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999;10:647–663
  6. Guyton AC. The kidneys and body fluids. In: Guyton AC, Hall JE, editors. Textbook of Medical Physiology. Philadelphia: WB Saunders Company; 1996. p. 308–72
  7. Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987;82:1213–1219
  8. Ebert TJ, Cowley AW, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest. 1986;77:1136–1142
  9. Sampey DB, Burrell LM, Widdop RE. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. Am J Physiol. 1999;276:R872–879
  10. Khayyal MA, Eng C, Franzen D, et al.  Effects of vasopressin on the coronary circulation (reserve and regulation during ischemia). Am J Physiol. 1985;248:H516–522
  11. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin (role of V1- and V2-vasopressinergic receptors). Am J Physiol. 1988;255:H261–265
  12. Fujisawa S, Iijima T. On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. Jpn J Pharmacol. 1999;81:309–312
  13. Goldsmith SR, Francis GS, Cowley AW, et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385–1390
  14. Szatalowicz VL, Arnold PE, Chaimovitz C, et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–266
  15. Francis GS, Benedict C, Johnstone DE, et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure (a substudy of the Studies of Left Ventricular Dysfunction (SOLVD)). Circulation. 1990;82:1724–1729
  16. Goldsmith SR, Francis GS, Cowley AW. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol. 1986;58:295–299
  17. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol. 1998;449:415–426
  18. Xu DL, Martin PY, Ohara M, et al.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 1997;99:1500–1505
  19. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814–1820
  20. Goldsmith SR, Francis GS, Cowley AW, et al.  Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol. 1986;8:779–783
  21. Tahara A, Tomura Y, Wada K, et al.  Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res. 1998;38:198–205
  22. Nakamura Y, Haneda T, Osaki J, et al.  Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur J Pharmacol. 2000;391:39–48
  23. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999;195:93–98
  24. Bird E, Sasseville V, Dorso C, et al.  Significant reduction in cardiac fibrosis and hypertrophy in spontaneously hypertensive rats (SHR) treated with a V1a receptor antagonist. [abstract] Circulation. 2001;104(2 Suppl):186
  25. van der Bent V, Church DJ, Vallotton MB, et al.  i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol. 1994;266:H597–605 [Ca2+]
  26. Shoji M, Kimura T, Matsui K, et al.  Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system. Neuroendocrinology. 1986;43:239–244
  27. Yamamoto T, Kimura T, Ota K, et al.  Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am J Physiol. 1992;262:E856–862
  28. Creager MA, Faxon DP, Cutler SS, et al.  Contribution of vasopressin to vasoconstriction in patients with congestive heart failure (comparison with the renin angiotensin system and the sympathetic nervous system). J Am Coll Cardiol. 1986;7:758–765
  29. Clair MJ, King MK, Goldberg AT, et al.  Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther. 2000;293:852–860
  30. Nicod P, Waeber B, Bussien JP, et al.  Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol. 1985;55:1043–1047
  31. Ohnishi A, Orita Y, Takagi N, et al.  Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther. 1995;272:546–551
  32. Burrell LM, Phillips PA, Risvanis J, et al.  Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol. 1998;275:H176–182
  33. Yamamura Y, Nakamura S, Ito S, et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist (pharmacological profile and aquaretic effect by single and multiple oral dosing in rats). J Pharmacol Exp Ther. 1998;287:860–867
  34. Hirano T, Yamamura Y, Nakamura S, et al.  Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–294
  35. Naitoh M, Suzuki H, Murakami M, et al.  Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267:H2245–2254
  36. Serradeil-Le Gal C, Lacour C, Valette G, et al.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest. 1996;98:2729–2738
  37. Gheorghiade M, Niazi I, Ouyang J, et al.  Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure (a randomized, double-blind trial). [abstract] Circulation. 2000;102(2 Suppl):592
  38. Gheorghiade M, Konstam MA, Udelson JE, et al.  Vasopressin receptor blockade with tolvaptan in chronic heart failure (differential effects in normonatremic and hyponatremic patients). [abstract] J Am Coll Cardiol. 2002;39(5 Suppl A):171A
  39. Udelson JE, O’Brien T, Sequeira R, et al.  Vasopressin receptor blockade in patients with congestive heart failure (results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination). [abstract] J Am Coll Cardiol. 2002;39(5 suppl A):156A
  40. Gheorghiade M, Orlandi C, Gottlieb S, et al.  Vasopressin V2 receptor blockade versus fluid restriction in the treatment of hyponatremia (results from a multicenter randomized controlled trial). [abstract] Circulation. 2001;104(2 Suppl):438
  41. Chan PS, Coupet J, Park HC, et al.  VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol. 1998;449:439–443
  42. Abraham WT, Oren RM, Criseman TS, et al.  Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure. [abstract] J Am Coll Cardiol. 1997;29(2 Suppl A):169A
  43. Martin PY, Abraham WT, Lieming X, et al.  Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999;10:2165–2170
  44. Serradeil-Le Gal C. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev. 2001;19:201–214
  45. Tahara A, Tomura Y, Wada K, et al.  Pharmacological profile of YM087, a novel potent vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301–308
  46. Yatsu T, Tomura Y, Tahara A, et al.  Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol. 1997;321:225–230
  47. Yatsu T, Tomura Y, Tahara A, et al.  Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239–246
  48. Burnier M, Fricker AF, Hayoz D, et al.  Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999;55:633–637
  49. Udelson JE, Smith WB, Hendrix GH, et al.  Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  50. Painchaud CA, Ghazzi MM, Selaru P, et al.  Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure. [abstract] Circulation. 2000;102(2 Suppl):535
  51. Smith WB, Russell S, Ghali JK, et al.  Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients. [abstract] J Am Coll Cardiol. 2001;37(2 suppl A):172–173A

☆ Guest Editor for this manuscript was James B. Young, MD, Cleveland Clinic Foundation, Cleveland, Ohio,

PII: S0002-8703(02)94708-3

doi: 10.1016/S0002-8703(02)94708-3

American Heart Journal
Volume 146, Issue 1 , Pages 9-18 , July 2003

Article Tools